Chimeric Therapeutics Ltd (CHM) - Total Liabilities

Latest as of December 2025: AU$8.96 Million AUD ≈ $6.34 Million USD

Based on the latest financial reports, Chimeric Therapeutics Ltd (CHM) has total liabilities worth AU$8.96 Million AUD (≈ $6.34 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Chimeric Therapeutics Ltd - Total Liabilities Trend (2020–2025)

This chart illustrates how Chimeric Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. See CHM current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Chimeric Therapeutics Ltd Competitors by Total Liabilities

The table below lists competitors of Chimeric Therapeutics Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Boxlight Corp Class A NASDAQ:BOXL	USA	$92.68 Million
M N C Wireless Bhd KLSE:0103	Malaysia	RM8.80 Million
Olivut Resources Ltd V:OLV	Canada	CA$28.58K
CLS Holdings plc LSE:CLI	UK	GBX1.03 Billion
Sure-Tech Investments LP TA:STEC	Israel	ILA1.31 Million
MW Trade S.A. WAR:MWT	Poland	zł3.08 Million
Dart Mining NL AU:DTM	Australia	AU$719.72K

Liability Composition Analysis (2020–2025)

This chart breaks down Chimeric Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Chimeric Therapeutics Ltd (CHM) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.69	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	0.34	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-2.96	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	1.51	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Chimeric Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Chimeric Therapeutics Ltd (2020–2025)

The table below shows the annual total liabilities of Chimeric Therapeutics Ltd from 2020 to 2025.

Year	Total Liabilities	Change
2025-06-30	AU$19.60 Million ≈ $13.87 Million	+53.06%
2024-06-30	AU$12.80 Million ≈ $9.06 Million	-23.40%
2023-06-30	AU$16.71 Million ≈ $11.83 Million	+82.21%
2022-06-30	AU$9.17 Million ≈ $6.49 Million	-19.35%
2021-06-30	AU$11.37 Million ≈ $8.05 Million	+17670.20%
2020-06-30	AU$64.01K ≈ $45.29K	--

About Chimeric Therapeutics Ltd

AU:CHM Australia Biotechnology

Market Cap

$2.38 Million

AU$3.37 Million AUD

Market Cap Rank

#29763 Global

#1739 in Australia

Share Price

AU$0.07

Change (1 day)

-7.14%

52-Week Range

AU$0.00 - AU$0.21

All Time High

AU$0.39